91 results on '"Pawarode, Attaphol"'
Search Results
2. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
3. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
4. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
5. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease
6. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors
7. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
8. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
9. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
10. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
11. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
12. Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.
13. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
14. Survival following allogeneic transplant in patients with myelofibrosis
15. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
16. Is age a risk factor for cognitive changes following hematopoietic cell transplantation?
17. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
18. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation
19. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research
20. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
21. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia
22. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease
23. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
24. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
25. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma
26. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
27. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease
28. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis
29. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study
30. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial
31. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
32. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series
33. Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
34. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial
35. TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes
36. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission
37. Subcutaneous Panniculitis-Like T-Cell Lymphoma With Bone Marrow Involvement
38. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins
39. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities
40. Independent risk factors and natural history of renal dysfunction in liver transplant recipients
41. Outcomes of primary hepatocellular carcinoma treatment: An 8-year experience with 368 patients in Thailand
42. The utility of cognitive changes in identifying those with acute graft vs. host disease following allogeneic hematopoietic cell transplant.
43. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a CIBMTR analysis.
44. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
45. Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia.
46. Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia
47. A Phase I/II Clinical Trial of Type 1 Interferon for Reduction of Relapse after HCT in High Risk AML.
48. Phase 1 Study of Carfilzomib in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies.
49. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
50. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.